Free Trial

→ Buffett, Gates and Bezos Quietly Dumping Stocks (From Paradigm Press) (Ad)

Top Dividend Stocks for Long-Term Investors - 3 of 15

Slide 3

Royalty Pharma (NASDAQ:RPRX)

Dividend Yield: 2.65%
Consensus Rating: Buy
Rating Score: 3.3
Ratings Breakdown: 4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $42.50 (24.9% Upside)

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. More

Insider Trades by Quarter for Royalty Pharma (NASDAQ:RPRX)

Slide 3

More From MarketBeat

web analytics

Get 30 Days of MarketBeat All Access for Free

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools.

Start Your 30-Day Trial

Sign in to your free account to enjoy these benefits

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

Sign In
Create Account

Your Email Address:

Your Password:

Log In

or

Sign in with Google

Forgot your password?

Your Email Address:

Choose a Password:

or

Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.